Status:
COMPLETED
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Chronic Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.
Detailed Description
In this exploratory investigation, we propose to study the adjuvant therapeutic efficacy and safety of galantamine in 20 patients with chronic schizophrenia, who are maintained on a stable regimen of ...
Eligibility Criteria
Inclusion
- Fulfills DSM-IV criteria for schizophrenia.
- Unable to achieve competitive employment status within the past five years.
- Unable to live independently in the community.
- Maintained on a stable regimen of antipsychotic medication for at least two weeks prior to enrollment.
Exclusion
- History of significant hepatic, renal, pulmonary, endocrine, active peptic ulcer disease or cardiovascular disease.
- History of seizure disorder and/or head injury.
- Co-morbid substance use/abuse disorder.
- Received an investigational medication within the previous month.
- Due to the risk of adverse effects on fetal development: women with any risk of becoming pregnant will be excluded from this study.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00161044
Start Date
September 1 2004
End Date
September 1 2005
Last Update
March 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maryland Psychiatric Research Center
Catonsville, Maryland, United States, 21228